Gynecologic Cancer

I always enjoyed writing about my summers, but this is what I would write today.

I faced cancer thrice and chose life each time — not because of some flowery will to live, but because I’m stubborn and wanted to prove that cancer is not the boss of me.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

Jemperli plus chemotherapy has been approved for the treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high endometrial cancer.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

The Food and Drug Administration approved Jemperli with chemotherapy and then alone for patients with dMMR or MSI-H advanced endometrial cancer.

Patients with HER2-expressing cancers using Enhertu saw significant improvements in progression-free survival and overall survival.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Adding Keytruda to chemoradiotherapy significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

While inflammation may not be associated with certain cancer-related symptoms, it can impact depression and physical activity levels in anyone, recent research showed.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

Researchers are looking for other ways to disrupt tumor cells in a way that better engages the immune system by exposing it to tumor antigens.

While my taste buds have returned to normal after cancer treatment, my desire to cook and eat has not.

Treatments for advanced endometrial cancer have progressed and improved with the use of immunotherapy with chemotherapy.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.

Results of the Canadian Cancer Trials Group CX.5/SHAPE trial could lead to surgical de-escalation among patients with cervical cancer.

I lost my hair during cancer treatment, but now that it’s growing back, I no longer obviously look like a patient.

The benefit obtained from Keytruda plus chemotherapy in patients with persistent, recurrent or metastatic cervical cancer occurred regardless of whether they also received Avastin.

After going through cancer, Mother’s Day feels a bit different.

Patients with advanced or recurrent endometrial cancer derived a survival benefit from Jemperli plus chemotherapy.

Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.

Researchers used an AI model to identify patients with endometrial cancer who had a low or high risk for cancer returning to another part of the body, also known as distant recurrence.

This analysis of the KEYNOTE-826 trial focused on health-related quality of life in patients with persistent, recurrent or metastatic cervical cancer.

Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.

Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.

Cryocompression was found to be tolerable and effective in preventing chemotherapy-induced peripheral neuropathy in a small study.

The Food and Drug Administration approved Keytruda for adult and pediatric patients with previously treated unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

The way I see it, double the cancer diagnoses means double the victory.